S&P 500 Industrials Sector SEC Filings — March 04, 2026

04-03-2026

04-03-2026

Ocugen reported Q4 and FY 2025 financial results with R&D expenses increasing to $10.7M (Q4, +29% YoY) and $39.8M (FY, +24% YoY), G&A expenses slightly down to $6.1M in Q4 (-3% YoY) but up to $27.6M FY (+3% YoY), wider net losses ($0.06/share Q4 vs $0.05, $0.23/share FY vs $0.20), and cash declining sharply to $18.9M from $58.8M, though bolstered by $22.5M raised in Jan 2026 extending runway to Q4 2026. Significant clinical progress includes completed enrollment in OCU400 Phase 3 liMeliGhT trial (140 patients, topline Q1 2027) and positive OCU410 Phase 2 preliminary data (46% lesion growth reduction vs control, p=0.015). OCU410ST Phase 2/3 nearing enrollment completion with interim data Q3 2026.

• ·OCU410ST Phase 2/3 GARDian trial enrollment nearing completion in Q1 2026; interim data Q3 2026, topline Q2 2027
• ·OCU400 first regional licensing agreement with Kwangdong for Korea (upfront, milestones, royalties)
• ·OCU200 Phase 1/2 no SAEs or AEs related to product to date; enrollment completion Q1 2026
• ·OCU500 Phase 1 to initiate Q2 2026 by NIAID
• ·Total liabilities $55.7M as of Dec 31, 2025 vs $52.8M prior year

04-03-2026

Global Water Resources reported full-year 2025 revenue growth of 5.8% YoY to $55.8 million, driven by the acquisition of seven water systems from Tucson Water, organic connection growth of 3.2%, and higher rates, with total active service connections up 6.3% to 68,577 and water consumption increasing 5.9% to 4.28 billion gallons. However, net income declined 48.9% YoY to $3.0 million due to higher depreciation, interest expenses from a $67.3 million capital investment plan, and a $1.3 million loss on asset disposals related to the Southwest Plant recommissioning; Adjusted EBITDA was nearly flat, decreasing 0.7% to $26.5 million. The company declared monthly dividends of $0.02533 per share ($0.30396 annualized) and secured a $15 million term loan at 5.49% on December 10, 2025, while pursuing a rate case for a $4.3 million annual revenue increase.

• ·Water service revenue increased to $28.6M (+9.8% YoY), while wastewater/recycled water revenue rose modestly to $27.1M (+2.0% YoY).
• ·Operating expenses rose 12.2% to $48.6M, driven by operations and maintenance up 14.7%, depreciation up 17.9%, and general/admin up 5.8%.
• ·Acquisition of seven Tucson Water systems in July 2025 at 1.05x rate base.
• ·Rate case hearings commence August 2026, expected conclusion late 2026.
• ·Conference call scheduled for March 5, 2026 at 1:00 p.m. ET.

04-03-2026

Black Rock Coffee Bar, Inc. (BRCB) grew total stores to 181 from 149 with 32 net new openings, boosting total revenue 24.5% YoY to $200.3M and same-store sales growth to 10.1% from 6.3%, while average unit volume rose to $1.286M from $1.186M. However, income from operations plummeted 85.1% to $0.9M from $6.0M, and net loss widened 130.1% to $16.5M from $7.2M, driven by SG&A expenses surging 63.6% to $41.3M amid rising store operating costs.

• ·Store operating costs and expenses rose 22.2% YoY to $141.6M, with other store operating expenses up 28.4%.
• ·Pre-opening costs increased 28.2% to $4.3M.
• ·Interest expense, net improved 15.9% to $9.4M due to lower expense.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 4, 2026, announcing the issuance of a press release titled 'AITX's RAD Channel Partner Expands Detection to Guard Response Ecosystem,' attached as Exhibit 99.1. The filing discloses a positive development in channel partner expansion integrating detection capabilities into the Guard Response Ecosystem. No financial impacts or quantitative metrics were reported.

04-03-2026

Archimedes Tech SPAC Partners II Co. reported total assets of $241.3M as of December 31, 2025, primarily from $239.9M in its Trust Account following its February 12, 2025 IPO of 23M Units, with net income of $8.0M for the year driven by $8.7M in interest income. However, operating losses reached $0.8M from G&A expenses, shareholders' deficit expanded to $6.7M due to $24.6M accretion on redeemable shares, compared to a minor $54k deficit at year-end 2024 pre-IPO. The 2024 inception period showed a $79k net loss with negligible assets.

• ·IPO consummated on February 12, 2025, with full exercise of 3M over-allotment option; 750k sponsor shares no longer subject to forfeiture.
• ·Company inception date: June 7, 2024.
• ·Ordinary shares subject to redemption valued at $10.43 per share as of Dec 31, 2025.
• ·Promissory note to related party of $192k repaid by Dec 31, 2025.

04-03-2026

NexGen Energy Ltd. filed its Form 40-F annual report for FY ended December 31, 2025, incorporating the Annual Information Form, MD&A, and audited IFRS financial statements for 2025 and 2024, with 659,960,072 common shares outstanding. Short-term compensation to key management personnel decreased 1.4% YoY to $5,950, while share-based payments increased 30.9% YoY to $32,397. Management confirmed effective disclosure controls and no material changes in internal controls over financial reporting.

• ·Audited by KPMG LLP (Auditor Firm ID: 85)
• ·Principal executive offices: Suite 3150, 1021 West Hastings Street, Vancouver, B.C., Canada V6E 0C3
• ·Agent for service in US: Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, Delaware 19711
• ·No off-balance sheet arrangements material to investors
• ·No changes in internal control over financial reporting during FY2025

04-03-2026

MOVING iMAGE TECHNOLOGIES INC. (MITQ) issued a DEFA14A additional proxy statement for its Annual Meeting of Stockholders on March 12, 2024, at 10:00 a.m. local time. Proposals include electing five directors for a one-year term expiring at the 2025 annual meeting and ratifying Haskell & White LLP as independent auditors for the fiscal year ending June 30, 2024. The Board recommends voting 'FOR' both proposals.

• ·Meeting location: 17760 Newhope Street, Suite B, Fountain Valley, CA 92708
• ·Fiscal year reference for audit ratification: ending June 30, 2024
• ·Prior year reference: year ended June 30, 2023 (investor site link)

04-03-2026

Babcock & Wilcox reported Q4 2025 revenue of $161.0 million, essentially flat YoY compared to $161.8 million, but delivered strong profitability with operating income of $12.2 million (up from $2.6 million) and Adjusted EBITDA of $16.4 million (53% increase from $10.7 million). Full year 2025 revenue increased slightly by 1.2% to $587.7 million alongside a 107% surge in Adjusted EBITDA to $43.7 million, though the company still recorded a $32.8 million loss from continuing operations (improved from $104.3 million prior year). Key highlights include signing full notice to proceed on a $2.4 billion AI data center project with Base Electron, boosting continuing operations backlog to $2.8 billion (470% YoY increase) and reducing net debt to $119.7 million.

• ·Paid off outstanding bonds due February 2026 in December 2025; plans to pay off December 2026 bonds in 2026.
• ·Earnings conference call scheduled for March 16, 2026 at 5 p.m. ET.
• ·Extended maturity date of Axos facility.

04-03-2026

EyePoint Pharmaceuticals reported Q4 2025 net revenue of $0.6M, down 95% YoY from $11.6M, and full-year revenue of $31.4M, down 28% from $43.3M, primarily due to lower license and royalty revenue recognition from the YUTIQ agreement, while operating expenses rose 25% to $71.0M in Q4 and 45% to $274.8M for the year driven by Phase 3 trials. Net losses widened to $67.6M ($0.81/share) in Q4 and $232.0M ($3.17/share) for the year. However, cash and investments stood at $306M, providing runway into Q4 2027, with DURAVYU Phase 3 wet AMD trials (LUGANO/LUCIA) on track for mid-2026 topline data and first patients dosed in DME trials (COMO/CAPRI).

• ·U.S. patent issued in February 2026 extending DURAVYU insert formulation coverage into 2043.
• ·Manufacturing of registration batches for DURAVYU completed at Northbridge, MA facility for NDA CMC section.
• ·DSMC recommended continuation of Phase 3 wet AMD program with no modifications after second review.

04-03-2026

The Real Brokerage Inc. (REAX) filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form, audited consolidated financial statements, and Management’s Discussion and Analysis. The company reported 210.5 million outstanding common shares as of December 31, 2025, with no long-term debt, capital leases, operating leases, purchase obligations, or other long-term liabilities (all $0). No material changes in internal control over financial reporting were noted, and the Audit Committee is led by financial expert Larry Klane.

• ·No changes in internal control over financial reporting during FY 2025.
• ·No off-balance sheet arrangements.
• ·Shareholder quorum requirement: at least 5% of issued common shares.
• ·Exempt from certain Nasdaq rules as foreign private issuer (e.g., proxy solicitation follows Canadian rules).
• ·Code of Business Conduct and Ethics applies to all directors, officers, and employees.

04-03-2026

Bath & Body Works reported Q4 2025 net sales of $2.7B, down 2% YoY from $2.8B, with adjusted EPS of $2.05 slightly below prior year's $2.09, though results exceeded guidance; FY 2025 net sales were $7.3B, down 0.2% YoY, with adjusted EPS of $3.21 versus $3.29 last year and operating income declining to $1.1B from $1.3B. The company repurchased $400M in shares and ended with $953M in cash, up from $674M, but FY 2026 guidance projects net sales down 2.5-4.5% and adjusted EPS of $2.40-$2.65.

• ·U.S./Canada stores sales down 2.6% in Q4 but up 0.9% FY; Direct channel down 5.4% FY; International up 8.6% Q4 and 4.9% FY.
• ·Net cash from operating activities $1.1B in FY2025, up from $886M.
• ·Long-term debt reduced to $3.6B from $3.9B.
• ·Q1 2026 adjusted EPS guidance $0.24-$0.30 vs. $0.49 reported in Q1 2025.

04-03-2026

Abercrombie & Fitch Co. reported record Q4 FY2025 net sales of $1.7B, up 5% YoY with comparable sales +1%, and FY2025 net sales of $5.3B, up 6% YoY with comparable sales +3%, driven by Hollister's 15% FY growth while Abercrombie declined 1% FY. However, FY operating margin fell to 13.3% from 15.0% prior year, Q4 margin dropped to 14.1% from 16.2%, and FY EPS was $10.46 vs $10.69 prior. The company repurchased 5.4M shares for $450M (11% of shares outstanding) and outlooked FY2026 net sales growth of 3-5% with operating margin of 12.0-12.5%.

• ·Cash and equivalents flat at ~$760M YoY; inventories up to $601M from $575M.
• ·Liquidity stable at $1.2B.
• ·FY2026 outlook includes Q1 sales growth 1-3%, op margin ~7%; assumes 15% US tariff impact (290bps Q1, 70bps FY).
• ·Depreciation and amortization $155M FY2025 vs $154M FY2024.

04-03-2026

Edible Garden AG Incorporated entered into a Note Purchase Agreement dated March 3, 2026, with Streeterville Capital, LLC, issuing a secured promissory note with $1.625M principal for a $1.5M purchase price, incorporating a $120K original issue discount and $5K transaction expenses. The note is secured by all company assets (excluding Tetra Pak-related property) and guaranteed by subsidiaries 2900 Madison Ave Holdings, LLC and Edible Garden Corp., providing immediate cash influx but imposing restrictive covenants limiting future debt, equity issuances, and liens. While offering liquidity, the high OID signals elevated financing costs amid ongoing obligations.

• ·Closing Date: March 3, 2026, via electronic signatures at offices in Lehi, Utah
• ·Collateral excludes all assets, equipment, or property purchased from Tetra Pak, Inc. (including replacements and proceeds)
• ·Covenants restrict Restricted Issuances, new liens (except Tetra Pak assets), subsidiary equity/debt changes, and require timely SEC filings and listing maintenance on NYSE/Nasdaq American

04-03-2026

On March 3, 2026, Hexcel Corporation entered into a Cooperation Agreement with Vision One Fund, LP and affiliates, appointing Neal J. Keating to the Board of Directors and Audit Committee, nominating him for the 2026 Annual Meeting, and limiting Board size to 10 directors until the 2026 Annual Meeting and 9 thereafter until the Expiration Date. Vision One Parties agreed to withdraw their 2026 Annual Meeting nominees, adhere to standstill restrictions, and vote for Board nominees. No financial terms or impacts were disclosed.

• ·Board size limited to no more than 10 directors until 2026 Annual Meeting and 9 directors from 2026 Annual Meeting until Expiration Date (earlier of 30 days prior to 2027 stockholder nomination deadline or 150 days prior to 2026 Annual Meeting one-year anniversary).
• ·Neal J. Keating, age 70, previously Chairman, President, and CEO of Kaman Corporation (2008-2020), Executive Chairman until 2021; COO of Hughes Supply; CEO of GKN Aerospace.
• ·Mr. Keating serves on Hubbell Incorporated board since 2010 (chairs nominating/governance committee); former lead director of Triumph Group (2022-July 2025) and Barnes Group Inc. (2023-2025).
• ·No arrangements or understandings other than Cooperation Agreement for appointment; no reportable related party transactions under Item 404(a).

04-03-2026

Grayscale Bittensor Trust (TAO) announced a change in the index used for valuing its Bittensor (TAO) holdings, switching from the Coin Metrics Real-Time Rate to the CoinDesk Bittensor Benchmark Rate effective March 6, 2026, for NAV and NAV per Share calculations. The new index employs a volume-weighted algorithm from Constituent Trading Platforms selected based on IOSCO-aligned criteria including market quality, security, regulatory compliance, and others. Detailed methodology covers platform selection, price determination every 5 seconds, outlier detection, inactivity adjustments, and contingency plans if the index is unavailable.

• ·Index Price calculated every 5 seconds over 24-hour period at 4:00 p.m. New York time on business days
• ·Registration Statement on Form 10 filed December 9, 2025
• ·Index License Agreement dated February 1, 2022
• ·Constituent Trading Platforms must serve customers in jurisdictions including US (FinCEN), UK (FCA), EU (MiCA), Hong Kong (SFC), Singapore (MAS), UAE (VARA, ADGM), Gibraltar (GFSC)

04-03-2026

Tevogen Bio Holdings Inc. adopted a Certificate of Amendment to its Certificate of Incorporation, authorizing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, at 12:01 a.m. ET, with no fractional shares issued and cash payments in lieu thereof. Authorized capital stock remains 820M total shares, comprising 800M common shares and 20M preferred shares, each with $0.0001 par value. The amendment was approved by the Board and stockholders without changes to other sections.

• ·Reverse split applies automatically without further action by holders.
• ·Filed with Delaware Secretary of State; executed March 3, 2026.

04-03-2026

Boxabl Inc. issued a promotional newsletter via StockTwits highlighting its SPAC merger with FG Merger II Corp. (FGMC), including a deadline extension to March 31, 2026, pending regulatory and shareholder approvals, following the merger agreement signed on August 4, 2025. Boxabl touted its $230M crowdfunding from over 60,000 investors since 2020 and products like the 361 sq ft Casita and 120 sq ft Baby Box. However, the communication emphasizes significant risks, including potential shareholder redemptions, regulatory delays, historical net losses, and failure to achieve commercialization.

• ·Boxabl founded in 2017
• ·FGMC final prospectus filed with SEC on January 29, 2025
• ·Boxabl Annual Report on Form 10-K filed April 14, 2025
• ·FGMC CIK: 1816937
• ·Surviving entity to be renamed BOXABL Inc. with ticker $BXBL
• ·FGMC address: 104 S. Walnut Street, Unit 1A, Itasca, Illinois 60143
• ·Boxabl address: 5345 E North Belt Rd, Las Vegas NV 89115

04-03-2026

Citius Oncology, majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced positive topline Phase 1 data from an investigator-initiated trial of LYMPHIR™ (denileukin diftitox-cxdl) administered prior to commercial CD19 CAR-T therapy in 14 high-risk relapsed/refractory DLBCL patients, showing 86% ORR (57% CR, 29% PR), 77% 1-year PFS, and 84% 1-year OS. LYMPHIR was well-tolerated with no dose-limiting toxicities, effective Treg depletion, and manageable low-grade adverse events including 43% CRS and 21% ICANS. The data supports further exploration in larger studies to enhance CAR-T efficacy.

• ·LYMPHIR doses tested: 5, 7, or 9 µg/kg
• ·Median Treg reduction: 24 Tregs/µL (range 8–65), nadir at 24 hours post-dose
• ·LYMPHIR FDA-approved and launched in U.S. December 2025 for relapsed/refractory CTCL
• ·License acquired in 2021 for markets excluding India, Japan, and certain Asia

04-03-2026

Moody’s Corporation's 2026 Proxy Statement outlines the virtual Annual Meeting of Stockholders on April 14, 2026, at 9:30 a.m. EDT, with stockholders voting on electing ten director nominees for one-year terms, ratifying KPMG LLP as independent auditors for 2026, and an advisory resolution on executive compensation. The record date is February 18, 2026, and proxy materials were made available starting March 4, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/MCO2026
• ·Company address: 7 World Trade Center, 250 Greenwich Street, New York, New York 10007
• ·Investor Relations contact: ir@moodys.com or (212) 553-0300
• ·2025 Annual Report covers year ended December 31, 2025

04-03-2026

AmBase Corporation entered into a Litigation Funding Agreement (RAB 2026 LFA) with CEO Richard A. Bianco for up to $6M to fund operations and the 111 West 57th Property litigation, including conversion of $4M existing promissory notes and $2M in new cash infusions. BARC Investments LLC simultaneously converted its $2M note (plus ~$200k accrued interest) into a pari-passu LFA (BARC 2026 LFA). However, these deals dilute future litigation proceeds significantly, with funders prioritized for up to 1.8x multiples on funding amid persistent going concern qualifications and uncertain litigation outcomes requiring additional capital.

• ·Accrued interest on RAB and BARC notes matures in 3 years from end of execution month.
• ·Funding approved by Special Committee of one independent director, advised by outside counsel.
• ·Litigation funding terms evaluated as fair despite prior unsuccessful third-party funding search.
• ·Company continues to seek additional capital; no assurance of success or litigation recovery.

04-03-2026

Old Second Bancorp, Inc. (OSBC) announced on March 4, 2026, its intention to redeem $30M aggregate principal amount of its 3.50% Fixed-to-Floating Rate Subordinated Notes due 2031 on April 15, 2026, at 100% of principal plus accrued and unpaid interest. The company has received non-objection from the Federal Reserve Bank of Chicago for the redemption. Following the redemption, $30M aggregate principal amount of the Notes will remain outstanding.

• ·Notes originally issued on April 6, 2021.
• ·Redemption to be made only upon presentation and surrender of Notes to the Paying Agent.
• ·Interest on redeemed Notes will cease to accrue on and after April 15, 2026.

04-03-2026

Sturm, Ruger & Company, Inc. (RGR) hosted a post-earnings release conference call and webcast on March 2, 2026, to discuss its 2025 financial results, with the transcript furnished as Exhibit 99.1 under Regulation FD Disclosure. The information is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act. A replay is available on the company's website at Ruger.com/corporate.

• ·Securities registered: Common Stock, $1 par value (RGR) on NYSE; Common Stock Purchase Rights (N/A) on NYSE.
• ·Filing signed by Thomas A. Dineen on March 4, 2026.

04-03-2026

Regen BioPharma, Inc. issued 77,849,847 common shares between February 4 and February 27, 2026, to satisfy $53,474 in principal convertible indebtedness, $4,249 in accrued interest, and $11,000 in fees, totaling approximately $68,723 in obligations. This unregistered issuance under Section 4(a)(2) was conducted directly through management without underwriters or commissions. As of March 3, 2026, the company has 212,318,424 common shares issued and outstanding, representing significant dilution for existing shareholders.

• ·Shares issued pursuant to Section 4(a)(2) of the Securities Act with no underwriters, commissions, advertisement, or general solicitation.
• ·Issuance period: February 4 to February 27, 2026.

04-03-2026

Bankwell Financial Group, Inc. reported strong recovery in 2025 with net income surging 260% YoY to $35.2M from $9.8M in 2024, fueled by net interest income growth of 19% to $98.9M, total revenue up 25% to $108.3M, and provision for credit losses dropping sharply to $1.0M from $22.6M. Asset quality improved markedly with nonperforming assets to total assets at 0.49% versus 1.88% in 2024, and return on average assets rose to 1.09% from 0.31%. However, noninterest expenses increased 15% YoY to $58.8M due to higher salaries and professional services, while efficiency ratio improved modestly to 54.1% from 57.9%.

• ·Provision for credit losses declined to $1.0M in 2025 from $22.6M in 2024.
• ·Net (recoveries) charge-offs to average loans at -0.01% in 2025 vs 0.81% in 2024.
• ·Tier 1 capital to risk-weighted assets for Bankwell Bank at 11.87% in 2025 (up from 11.64%).
• ·Gains and fees from sales of loans jumped to $5.1M in 2025 from $0.5M in 2024.

04-03-2026

Rigetti Computing reported Q4 2025 total revenues of $1.9 million and full-year 2025 revenues of $7.1 million, alongside substantial losses including a Q4 operating loss of $22.6 million, Q4 GAAP net loss of $18.2 million, and FY GAAP net loss of $216.2 million. While financial performance remains weak with low revenues relative to losses, the company holds a strong cash position of $589.8 million and secured significant orders such as $8.4 million from C-DAC for a 108-qubit system and $5.7 million in Novera on-premises systems. Technological progress includes achieving 99.9% two-qubit gate fidelity at 28 nanosecond gate speed and advancements in chiplet-based 108-qubit systems.

• ·Japanese research organization Novera QPU order with delivery expected in April 2026
• ·C-DAC 108-qubit system deployment expected in second half of 2026
• ·Q4 2025 GAAP net loss per share $(0.06); non-GAAP $(0.03)
• ·FY 2025 GAAP net loss per share $(0.70); non-GAAP $(0.16)
• ·Anticipated significant Q1 2026 YoY revenue growth from Novera shipments
• ·Conference call held March 4, 2026 at 5:00 pm ET

04-03-2026

ImmuCell Corporation reported 2025 product sales of $27.6 million, up 4.3% YoY from $26.5 million, with gross margin expanding to 41.4% from 30% due to higher volumes (380,000 units/month vs. 345,000) and efficiencies, resulting in net operating income of $1.6 million versus a $1.6 million loss in 2024. However, the company posted a net loss of $1.0 million, improved from $2.2 million but driven by one-time charges including a $2.7 million Re-Tain asset write-down, $651,000 colostrum inventory write-down, and $297,000 CEO transition expenses; Q4 saw a net loss of $2.8 million versus a $0.5 million profit. Balance sheet showed stable cash at $3.8 million but a slight decline in stockholders' equity to $27.1 million from $27.5 million.

• ·EBITDA for 2025 was $2.2 million vs. $1.1 million in 2024.
• ·Cash from operating activities improved to $2.5 million in 2025 from $0.4 million in 2024.
• ·Total assets decreased to $42.5 million as of Dec 31, 2025 from $45.1 million as of Dec 31, 2024.
• ·Conference call scheduled for March 5, 2026 at 9:00 AM ET.

04-03-2026

ChargePoint reported Q4 FY2026 revenue of $109.3M, up 7% YoY, driven by 10% growth in networked charging systems and 11% in subscription revenue, with GAAP gross margin improving to 31% from 28%. However, full FY2026 revenue declined 1% YoY to $411.2M due to an 8% drop in networked charging systems despite 13% subscription growth, and while GAAP net loss narrowed to $220.2M from $277.1M, adjusted EBITDA loss widened slightly in Q4.

• ·Cash and cash equivalents: $141.6M as of January 31, 2026.
• ·Q1 FY2027 revenue guidance: $90M to $100M.
• ·ChargePoint network connects to over 1.37M charging ports worldwide and has facilitated 21B electric miles.
• ·Appointed Jaser Faruq as Chief Product and Software Officer.

04-03-2026

Horizon Bancorp, Inc. announced the elimination of the Chief Administration Officer position at the company and its subsidiary Horizon Bank, effective March 31, 2026, leading to the departure of Mark E. Secor, Executive Vice President and Chief Administration Officer, to pursue other opportunities. The departure is not related to any disagreement on financial, accounting, or other matters. In connection, the company expects to provide Mr. Secor with severance of one week of pay per full year of service (maximum 13 weeks) based on his then-current weekly rate, plus a pro-rated 2026 Executive Officer Bonus at target, subject to a seven-day revocation period.

• ·Announcement made on March 3, 2026
• ·SEC filing dated March 4, 2026
• ·Includes customary general release of claims, non-disclosure, non-disparagement, and confidentiality covenants

04-03-2026

On February 26, 2026, Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement, selling debentures with an aggregate principal amount of $200,000, bearing 0% interest and due April 27, 2026. The debentures are convertible into common stock upon consummation of a public offering at the offering price, subject to a 9.99% beneficial ownership limit, with potential issuance of warrants equal to 100-150% of related shares depending on timing. The transaction was consummated for $200,000 and exempt from registration under Section 4(a)(2) and Regulation D.

• ·Debentures maturity date: April 27, 2026, extendable by holder in 60-day increments.
• ·Warrants, if issued, exercisable immediately at Public Offering price, expire 5 years from issuance.
• ·Filing date: March 04, 2026; event date: February 26, 2026.

04-03-2026

Edgemode, Inc. entered into a securities purchase agreement on February 24, 2026, issuing a convertible promissory note with a $150,000 principal amount and $15,000 original issuance discount to CFI Capital LLC, receiving net proceeds of $130,000 after $5,000 in legal costs for working capital. The note accrues 6% annual interest payable in shares, matures on February 24, 2027, and becomes convertible after six months at 60% of the lowest trading price over the prior 15 trading days, with a 9.99% ownership cap. Standard events of default apply, potentially adjusting the conversion price to 45%.

• ·Promissory note prepayment subject to penalties and premiums.
• ·Issued in reliance on Section 4(a)(2) exemption from Securities Act registration.
• ·Events of default include failure to honor conversion notices, SEC reporting delays, or delisting from OTC Markets.

04-03-2026

Niagen Bioscience reported strong FY 2025 results with net sales up 30% YoY to $129.4M, net income surging 103% to $17.4M, and Adjusted EBITDA rising 139% to $20.4M, driven by Tru Niagen® (+27%) and Niagen ingredient sales (+45%). However, Q4 net income declined to $4.1M from $7.2M due to higher operating expenses and the absence of prior-year one-time benefits like royalty reversals, despite 16% sales growth to $33.8M. The company ended 2025 with $64.8M in cash (up from $44.7M) and guides for 10-15% sales growth in 2026 excluding the recently sold reference standards segment.

• ·Q4 2025 operating expenses increased 59% YoY to $17.6M, driven by higher G&A excluding prior-year benefits.
• ·FY 2025 selling and marketing expense improved to 27.4% of net sales (down 220 bps YoY).
• ·2026 G&A expected to increase $4.0M to $5.0M due to infrastructure, legal, and share-based compensation.
• ·Dec 2025 acquisition of core NR patent portfolio from Queen’s University Belfast.
• ·Nov 2025 launch of Tru Niagen® Beauty for skin, hair, and nail health.

04-03-2026

Federal Agricultural Mortgage Corporation (Farmer Mac) issued a press release on March 4, 2026, announcing the date and time of its upcoming Investor Day webcast to discuss growth opportunities and strategic priorities. The filing lists various registered securities including Class A and Class C common stock and multiple series of preferred stock. No financial results or performance metrics were disclosed.

04-03-2026

Cracker Barrel Old Country Store, Inc. reported Q2 FY2026 total revenue of $874.8 million, down 7.9% YoY from $949.4 million, driven by comparable store restaurant sales declining 7.1% and retail sales falling 9.2%. GAAP net income dropped to $1.3 million ($0.06 per diluted share) from $22.2 million ($0.99 per diluted share), with adjusted EBITDA decreasing to $38.2 million from $74.6 million. However, the company ended the quarter with total debt of $531.5 million and a low consolidated senior leverage ratio of 0.3x, expects a $46 million net cash benefit from litigation settlements in Q3, and updated its FY2026 outlook to $3.24-3.27 billion in revenue and $85-100 million adjusted EBITDA while declaring a $0.25 quarterly dividend.

• ·Six months FY2026 net loss of $23.3 million vs net income of $27.1 million prior year.
• ·Q2 FY2026 operating income of $0.5 million vs $29.1 million prior year (-98%).
• ·Capital expenditures outlook for FY2026: $105-115 million.
• ·2 new Cracker Barrel stores planned for FY2026.
• ·Quarterly dividend of $0.25 per share payable May 13, 2026 to shareholders of record April 10, 2026.

04-03-2026

NCS Multistage Holdings, Inc. filed a Form 8-K on 2026-03-04 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific quantitative financial metrics such as revenue, earnings, margins, or period-over-period comparisons are mentioned in the provided filing details. This appears to be a standard voluntary earnings-related disclosure with no detailed performance data available.

04-03-2026

Ardent Health reported Q4 2025 total revenue of $1.61B, down 0.1% YoY (or up ~3% adjusted for prior New Mexico payments) driven by 2.0% adjusted admissions growth offset by a 2.4% decline in net patient service revenue per adjusted admission, while Adjusted EBITDA fell 26.6% to $134M. Full-year 2025 showed revenue growth of 6.0% to $6.32B and Adjusted EBITDA expansion of 9.3% to $545M (margin +20bps), bolstered by operating cash flow surging 49% to $471M and net leverage improving to 2.5x with $710M cash. 2026 guidance projects revenue of $6.4-6.7B but Adjusted EBITDA of $485-535M, reflecting headwinds from payor denials and expense pressures despite IMPACT program savings of $55M.

• ·Q4 2025 net income $45M ($0.32 per diluted share) vs. $114M ($0.81 per diluted share) in Q4 2024.
• ·Available liquidity $1B as of Dec 31, 2025.
• ·$47M remaining under share repurchase authorization.
• ·2026 guidance: Net income $129-183M, diluted EPS $0.90-1.27, adjusted admissions growth 1.5-2.5%, capex $225-265M, REIT rent expense $168M.

04-03-2026

Liminatus Pharma, Inc. disclosed via 8-K an amendment to its Amended and Restated Bylaws, originally adopted on April 30, 2025, with the latest amendment adopted on February 27, 2026. The bylaws outline corporate offices, stockholder meeting procedures—including board control over annual and special meetings—and detailed advance notice requirements for director nominations and shareholder proposals, limiting special meetings to be called only by the Board, Chair, CEO, or President. These governance changes impose strict timelines (e.g., 120-150 days prior to annual meeting anniversary) and extensive disclosure obligations on proposing stockholders, with no financial impacts

04-03-2026

PepGen Inc. reported a slightly narrower net loss of $89.7M for the year ended December 31, 2025, compared to $90.0M in 2024, with operating expenses declining 4.2% YoY to $93.6M driven by a 7.1% drop in R&D expenses, though G&A rose 6.2%. Cash and equivalents grew 22.5% to $60.5M, bolstered by $108M net proceeds from a public offering, resulting in a net cash increase of $11.1M versus a $31.4M decrease prior year; however, interest income fell 43.7% to $4.0M and shares outstanding more than doubled to 68.9M, diluting EPS to $(2.12) from $(2.85). Total assets expanded 15.3% to $173.9M, but accumulated deficit widened to $361.1M.

• ·Stock-based compensation expense declined to $10.6M from $11.5M YoY.
• ·Net cash used in investing activities improved to $(15.2M) from $(37.7M), with lower purchases of marketable securities.
• ·Accumulated deficit increased to $361.1M from $271.5M.
• ·Employment agreements executed with executives on May 20, 2025 (Kasra Kasrarian, PhD), August 19, 2024 (Paul D. Streck), and December 8, 2025 (Joseph Vittiglio).

04-03-2026

On February 26, 2026, the Board of Directors of CoastalSouth Bancshares, Inc. appointed J. Simon Fraser as a director, effective immediately, with his term set to expire at the 2026 Annual Meeting of Stockholders, after which he is expected to join the Audit Committee and Nominating and Governance Committee. Mr. Fraser is determined to be an independent director under applicable SEC and NYSE standards. The appointment involves no arrangements with other persons, no family relationships, and only ordinary course loans from subsidiary Coastal States Bank.

• ·Loans to Mr. Fraser from Coastal States Bank were made in the ordinary course of business on substantially the same terms as comparable transactions with non-related persons, with no more than normal risk of collectability.
• ·No transactions between Mr. Fraser and the Company required to be reported under Item 404(a) of Regulation S-K, except the described loans.

04-03-2026

On March 4, 2026, Independent Bank Corp. (INDB) filed an 8-K under Item 8.01 announcing that Jeffrey Tengel, President and Chief Executive Officer of Rockland Trust Company and INDB, issued a letter to employees regarding a recently diagnosed medical condition, with the letter attached as Exhibit 99.1. The filing was signed by Patricia M. Natale, General Counsel. This disclosure raises potential concerns about leadership continuity.

04-03-2026

Fennec Pharmaceuticals Inc. announced on March 4, 2026, that the Tampa General Hospital Cancer Institute is initiating a real-world study evaluating the clinical utility of PEDMARK® (sodium thiosulfate injection) in reducing ototoxicity risk for adolescent, young adult, and adult cancer patients receiving cisplatin-based chemotherapy. This development supports expanded evidence for the product's use beyond pediatric indications. A copy of the press release is furnished as Exhibit 99.1.

04-03-2026

CPS Technologies reported record FY2025 revenue of $32.6M, up 54% YoY from $21.1M, driven by strong demand and expanded production, with Q4 revenue at $8.2M (+39% YoY from $5.9M) and gross margin improving to 14.6% from a -5.1% loss. However, Q4 operating loss narrowed to $(0.1M) from $(1.3M) amid higher SG&A expenses of $1.3M (up from $1.0M due to variable compensation and commissions), while full-year net income turned positive at $0.4M from a $3.1M loss. The company secured a $15.5M follow-on order and raised $9.5M net from a public offering on Oct 8, 2025, bolstering its balance sheet to $29.5M in total assets.

• ·Q4 FY2025 net income $12,594 ($0.00 per diluted share) vs Q4 FY2024 net loss $(995,153) ($0.07 per diluted share).
• ·FY2025 income from operations $443,974 vs FY2024 loss $(4,380,928).
• ·Total current assets $24.8M as of Dec 27, 2025 vs $14.2M as of Dec 28, 2024.
• ·Conference call scheduled for March 3, 2026 at 9:00 a.m. Eastern (dial-in: 1-844-943-2942, passcode 641664).

04-03-2026

AEO Inc. reported strong Q4 FY2025 results with total net revenue up 10% YoY to a record $1.8B, driven by +8% comparable sales including Aerie +23% and American Eagle +2%. However, full FY2025 revenue grew only 3% to $5.5B with American Eagle comps flat (0%), gross margin down 230 basis points to 36.9%, adjusted operating income down to $328M from $445M, and adjusted diluted EPS declining to $1.50 from $1.74. The company returned $341M to shareholders via buybacks and dividends, exited the Quiet Platform logistics business incurring $102M in charges, and provided FY2026 guidance for operating income of $390-410M.

• ·Q4 FY2025 GAAP operating profit $96M impacted by $84M impairments/restructuring; adjusted $180M (+27% YoY).
• ·FY2025 capex $261M; FY2026 guidance $250-260M.
• ·Q1 FY2026 outlook: comps high-single digit, operating income $20-25M.
• ·Cash and equivalents $239M at Jan 31, 2026 (down from $309M prior year); current ratio 1.52 (flat YoY).

04-03-2026

Genesis Energy, L.P. and Genesis Energy Finance Corporation closed a $750 million offering of 6.750% senior notes due May 15, 2034, on March 4, 2026, following the Underwriting Agreement dated February 18, 2026. Net proceeds will fund the redemption of all outstanding 7.75% senior notes due 2028 and general partnership purposes, including partial repayment of revolving borrowings under the senior secured credit facility. The new notes are senior unsecured obligations ranking equal with existing senior debt totaling $2.4 billion across maturities from 2029 to 2033.

• ·Interest on new notes accrues at 6.750% per year, payable semi-annually on March 15 and September 15, commencing September 15, 2026.
• ·Indenture governed by Base Indenture dated May 21, 2015, supplemented by Twenty-Fourth Supplemental Indenture dated March 4, 2026.

04-03-2026

Third Coast Bancshares, Inc. reported net income of $66.3M for the year ended December 31, 2025, up 39.1% YoY from $47.7M in 2024, fueled by net interest income growth of 21.4% to $195.2M and noninterest income increase of 28.5% to $13.7M, with net interest margin expanding to 4.06%. However, provision for credit losses rose 33.1% to $7.6M, signaling potential credit pressures, while noninterest expenses increased 13.6% to $118.5M. Compared to 2023, 2024 net income grew 42.7% to $47.7M.

• ·Average yield on gross loans declined slightly to 7.68% in 2025 from 7.80% in 2024.
• ·(Loss) gain on sale of investment securities available-for-sale worsened to ($0.6M) in 2025 from ($0.0M).
• ·Service charges and fees surged 55.1% YoY to $10.8M in 2025.
• ·Salaries and employee benefits, the largest noninterest expense, rose 18.5% to $77.2M.

04-03-2026

Bowman Consulting Group Ltd. reported record FY 2025 financial results with gross contract revenue up 14.9% YoY to $490.0M, net service billing up 14.5% to $434.8M, and adjusted EBITDA up 22.5% to $72.9M with margin expansion of 110 bps to 16.8%; gross backlog also grew 20.1% to $479.1M. However, Q4 net income declined to $2.0M from $5.9M due to a prior one-time $5.4M tax benefit, adjusted EBITDA margin remained nearly flat at 17.3% vs 17.2%, and FY organic net service billing growth slightly decreased to 12.4% from 13.1%. The company acquired RPT Alliance, raised 2026 net revenue guidance to $495-510M from $465-480M, increased its credit facility to $250M from $210M, and announced CEO Gary Bowman's planned retirement in 2026.

• ·Acquired RPT Alliance on December 8, 2025, expanding power and utilities practice.
• ·Entered Third Amendment to Credit Agreement on March 3, 2026, increasing revolving credit facility to $250M from $210M.
• ·Repurchased 272,885 shares in Q4 2025 at avg $34.25/share; 683,448 shares in FY 2025 at avg $27.51/share; additional 159,177 shares post-year end at avg $34.11/share.
• ·Cash from operations FY 2025: $35.8M vs $24.3M prior year.
• ·Dec 31, 2025 revolving credit facility balance: $95.4M vs $37.0M prior year.
• ·Over 2,300 employees across 135 US locations.
• ·Conference call scheduled March 5, 2026 at 9:00 a.m. ET.

04-03-2026

Designer Brands Inc. and its subsidiaries entered into a Third Amendment to their Credit Agreement on February 27, 2026, with The Huntington National Bank as Administrative Agent, primarily to extend the Maturity Date and amend certain provisions of the existing agreement originally dated March 30, 2022. The amendment's effectiveness is conditioned on, among other things, a Borrowing Base Certificate demonstrating Availability of no less than $90,000,000 as of January 31, 2026, confirmation of no Defaults or Events of Default, and no Material Adverse Effect since November 30, 2025. All Loan Documents are ratified and reaffirmed.

• ·Previous amendments: First Amendment on February 28, 2023; Joinder and Second Amendment on June 23, 2023.
• ·Conditions include recent lien searches revealing no impermissible Liens, favorable legal opinions from Vorys, Sater, Seymour and Pease LLP and Osler, Hoskin & Harcourt LLP, and payment of fees per Third Amendment Fee Letter.
• ·Governing law: State of New York.

04-03-2026

Unity Bancorp, Inc. reported strong FY2025 results with net income per diluted share up 39.7% to $5.67 from $4.06 in FY2024, driven by net interest income increasing 18.7% to $117.0 million and noninterest income surging 74.5% to $14.8 million. However, noninterest expenses rose $3.7 million to $52.4 million due to higher compensation, processing, and occupancy costs. Net income before provision for income taxes grew 38.8% to $75.5 million, with GAAP net income at $58.0 million versus $41.5 million prior year.

• ·Return on average assets improved to 2.17% from 1.68%.
• ·Return on average equity rose to 18.07% from 14.99%.
• ·Dividend payout ratio decreased to 10.23% from 12.81%.
• ·Adjusted net income (non-GAAP) increased to $51.8M from $41.5M after adjustments for securities gains and credit loss releases.

04-03-2026

Alnylam Pharmaceuticals' Board granted CEO Yvonne Greenstreet a special performance-based equity award of 55,373 target performance share units valued at $18.0M based on the March 2, 2026 closing stock price of $325.07, vesting between 50% and 200% only if average stock price over a 30-day period in late 2029 reaches $500-$800 thresholds (54%-146% increases). Under her leadership, the company achieved nearly 100% stockholder return, met all 'Alnylam P5x25' goals including 2025 profitability, launched AMVUTTRA (including 2025 TTR cardiomyopathy approval), and advanced a pipeline with over 25 programs including three new Phase 3 trials. The award incentivizes achievement of 'Alnylam 2030' goals with full forfeiture if thresholds unmet.

• ·Special Award vesting measured by highest average closing price over 30 consecutive trading days in six months prior to December 31, 2029
• ·Award under Second Amended and Restated 2018 Stock Incentive Plan
• ·Full forfeiture if average stock price does not reach $500 threshold
• ·Form of award agreement to be filed in Q1 2026 10-Q

04-03-2026

WesBanco, Inc.'s Board reduced its size from 19 to 15 directors effective after the April 2026 Annual Meeting, accepting voluntary retirements from Abigail M. Feinknopf, James W. Cornelsen, D. Bruce Knox, and Michael J. Crawford (the latter due to age policy), with no disagreements on company matters. Retiring directors received a one-time equity grant of restricted common stock valued at $250,000. To balance board classes, John L. Bookmyer and Joseph R. Robinson were reclassified and nominated for election at the 2026 Annual Meeting.

• ·Retirements and board size reduction effective at conclusion of 2026 Annual Meeting in April 2026.
• ·Bookmyer nominated for three-year term expiring 2029; Robinson for one-year term expiring 2027.
• ·Reclassifications of Bookmyer and Robinson solely for class balance; service deemed uninterrupted for committees and compensation.

04-03-2026

On February 26, 2026, Chui Tin Mok, an executive director on the Board of Faraday Future Intelligent Electric Inc., notified the Board of his intent to resign upon confirmation of a successor to focus on business execution in the UAE and Middle East. He will continue serving as an executive officer and Head of FF Middle East. The resignation has no immediate impact as no successor is yet named.

• ·Trading symbols: FFAI (Class A common stock), FFAIW (redeemable warrants) on Nasdaq Stock Market LLC
• ·Company confirmed as emerging growth company
• ·Business address: 18455 S. Figueroa Street, Gardena, CA 90248
• ·Former name: Property Solutions Acquisition Corp. (changed March 4, 2020)

04-03-2026

RB Global, Inc. announced on March 4, 2026, that it has entered into a definitive agreement to acquire Big Iron Auction Company. A news release with further details is attached as Exhibit 99.1 and incorporated by reference into the filing. No financial terms, metrics, or performance data were disclosed in the 8-K.

04-03-2026

Fifth Third Bancorp completed its acquisition of Comerica Incorporated on February 1, 2026, pursuant to the Agreement and Plan of Merger dated October 5, 2025. This 8-K/A amends the original February 2, 2026 filing to include Comerica's audited consolidated financial statements as of and for the years ended December 31, 2024, 2023, and 2022, unaudited statements as of and for periods ended September 30, 2025, and unaudited pro forma condensed combined financial information for Fifth Third as of September 30, 2025 and relevant income periods. No specific performance metrics or changes are detailed in the filing text.

• ·Original 8-K filed February 2, 2026
• ·Comerica audited financials cover fiscal years ended December 31, 2024, 2023, 2022
• ·Pro forma balance sheet as of September 30, 2025; income statements for nine months ended September 30, 2025 and year ended December 31, 2024 assuming Transaction on January 1, 2024

04-03-2026

Great Lakes Dredge & Dock Corp (GLDD) filed SC 14D9 on March 4, 2026, disclosing multiple sets of FY2026E-2030E financial projections in response to a tender offer and potential merger, with revenue projected to grow from $864-900M in 2026E to $1,012M in 2030E and Adjusted EBITDA from $178-185M to $249M across scenarios. However, revenue shows a decline or flat performance in 2027E (e.g., $900M to $879M, -2.2% YoY), and Updated January 2026 projections reflect significantly lower Unlevered Free Cash Flow of $34M in 2026E versus prior estimates of $67-81M. Guggenheim Securities rendered a fairness opinion on February 10, 2026, stating the $17 per share offer price is fair from a financial point of view to shareholders.

• ·Capital expenditures projected at $87M in 2026E, declining to $24-25M in 2028E-2030E across recent projections.
• ·Taxes embedded in Unlevered Free Cash Flow calculations: $32M-$47M annually 2026E-2030E (excluding NOL balance).
• ·2025 Annual Report filed February 23, 2026.
• ·Guggenheim Securities engaged since October 28, 2025.

04-03-2026

Pasqal Holding SAS announced its business combination with Bleichroeder Acquisition Corp. II via a LinkedIn post and video on March 4, 2026, emphasizing the funding's role in accelerating commercialization, scaling neutral atom quantum processors deployed across 3 continents, and expanding globally in Europe, Asia Pacific, North America, and the Middle East. Leaders Wasiq Bokhari and Loïc Henriet highlighted increased system performance, industrial production, customer base growth, and plans for an initial NASDAQ listing in 2026 alongside a dual listing on Euronext. The communication includes forward-looking statements tempered by extensive risks, such as regulatory approvals, redemptions, and execution challenges.

• ·Final Prospectus filed by Bleichroeder on January 8, 2026
• ·Current Report on Form 8-K filed on January 9, 2026
• ·Upcoming Registration Statement on Form F-4 to include proxy statement/prospectus

04-03-2026

Goldenstone Acquisition Limited, a SPAC, is holding a Special Meeting on March 17, 2026, to vote on proposals including extending the business combination deadline from March 21, 2026, to December 21, 2026 (via monthly one-month extensions requiring $1,500 monthly deposits into the Trust Account), removing the restriction on targets headquartered in China (including Hong Kong and Macau), and changing the company name to 'Chi Special Acquisition Company'. The Trust Account holds $5,770,865 as of December 31, 2025, with redemption price ~$13.03 per share (vs. $11.51 closing price on Record Date), but failure to approve risks liquidation and redemption of all Public Shares. Sponsor holds 1,788,750 shares with voting rights in favor.

• ·Redemption deadline: two business days prior to Special Meeting (March 13, 2026)
• ·Special Meeting dial-in: US/Canada 1-800-450-7155 or +1-857-999-9155, Meeting ID 8376052#
• ·Prior Charter amendments: September 21, 2023; June 18, 2024; June 18, 2025
• ·Fiscal year end: March 31

04-03-2026

Totaligent, Inc. entered into an Extension Amendment on March 4, 2026, to its Binding Letter of Intent dated February 11, 2026, with Aetherium Medical, extending the target date for negotiating definitive agreements and closing the proposed acqui-hire transaction from March 5, 2026, to March 20, 2026. The binding exclusivity period remains unchanged through April 5, 2026. This amendment allows additional time for due diligence and negotiations without altering other LOI terms.

• ·Previous disclosure in Form 8-K filed February 12, 2026
• ·Company address: 3651 FAU Boulevard, Suite 400, Boca Raton, Florida 33431
• ·Telephone: (561) 360-3565